Lipid metabolism in pancreatic cancer treatment

Pancreatic cancer (PC) represents one of the most formidable challenges in oncology, necessitating continuous innovation in therapeutic strategies. Owing to its pivotal role in PC progression, lipid metabolism, which is characterized by dysregulated cholesterol biosynthesis, altered fatty acid profiles, and lipid-driven immunosuppression, has received increasing attention. These metabolic aberrations fuel tumour growth, chemoresistance, and metastasis while impairing immune surveillance. By targeting lipid pathways, emerging therapies hold promise for disrupting cancer cell survival and redefining PC treatment paradigms.